Profile data is unavailable for this security.
About the company
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
- Revenue in USD (TTM)220.04m
- Net income in USD-493.45m
- Incorporated1998
- Employees464.00
- LocationMorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
- Phone+49 89899270
- Fax+49 8 989927222
- Websitehttps://www.morphosys.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Avidity Biosciences Inc | 10.87m | -228.68m | 2.63bn | 253.00 | -- | 3.16 | -- | 241.69 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
Apogee Therapeutics Inc | 0.00 | -103.55m | 2.69bn | 91.00 | -- | 3.24 | -- | -- | -2.04 | -2.04 | 0.00 | 14.22 | 0.00 | -- | -- | 0.00 | -21.45 | -- | -22.20 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
Arcellx Inc | 131.66m | -50.54m | 2.71bn | 130.00 | -- | 5.43 | -- | 20.57 | -1.04 | -1.04 | 2.66 | 9.32 | 0.1877 | -- | -- | 1,012,792.00 | -7.21 | -38.82 | -8.96 | -45.41 | -- | -- | -38.39 | -339.38 | -- | -- | 0.0615 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
Azenta Inc | 651.76m | -152.26m | 2.71bn | 3.40k | -- | 1.24 | -- | 4.16 | -2.74 | -2.71 | 11.09 | 40.70 | 0.2242 | 2.86 | 3.44 | 186,216.00 | -5.24 | -0.5934 | -5.64 | -0.6725 | 40.04 | 43.08 | -23.36 | -2.17 | 5.26 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 2.72bn | 570.00 | -- | 6.61 | -- | 9.91 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
Denali Therapeutics Inc | 295.39m | -137.25m | 2.75bn | 375.00 | -- | 1.89 | -- | 9.30 | -0.9661 | -0.9661 | 2.09 | 10.21 | 0.1976 | -- | -- | 663,797.80 | -9.18 | -14.98 | -10.91 | -17.71 | -- | -- | -46.46 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
10X Genomics Inc | 625.45m | -264.30m | 2.75bn | 1.26k | -- | 3.82 | -- | 4.39 | -2.24 | -2.24 | 5.30 | 6.01 | 0.6458 | 2.67 | 7.39 | 496,781.60 | -27.29 | -25.52 | -30.80 | -29.05 | 64.62 | 75.88 | -42.26 | -48.53 | 4.45 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
Guardant Health Inc | 603.73m | -460.90m | 2.75bn | 1.78k | -- | 40.15 | -- | 4.56 | -3.92 | -3.92 | 5.17 | 0.5607 | 0.3754 | 4.37 | 7.03 | 339,362.00 | -28.66 | -22.26 | -33.02 | -24.59 | 60.37 | 64.62 | -76.34 | -97.07 | 5.66 | -59.55 | 0.9435 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
Morphosys Ag (ADR) | 220.04m | -493.45m | 2.78bn | 464.00 | -- | -- | -- | 12.62 | -3.39 | -3.42 | 1.56 | -1.88 | 0.1002 | 1.86 | 4.58 | 419,932.80 | -22.47 | -10.25 | -27.58 | -11.61 | 83.89 | 85.92 | -224.25 | -78.53 | 1.38 | -- | -- | -- | -14.37 | 25.53 | -25.60 | -- | 3.11 | -- |
Amicus Therapeutics, Inc. | 423.49m | -147.07m | 2.81bn | 517.00 | -- | 21.46 | -- | 6.62 | -0.493 | -0.493 | 1.42 | 0.4413 | 0.5955 | 1.00 | 5.86 | 819,127.70 | -20.68 | -30.65 | -25.76 | -36.55 | 89.62 | 88.94 | -34.73 | -86.10 | 2.61 | -1.36 | 0.7482 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.85bn | 988.00 | -- | -- | -- | 3.07 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.7975 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
Iovance Biotherapeutics Inc | 1.90m | -449.64m | 2.87bn | 557.00 | -- | 4.22 | -- | 1,507.92 | -1.82 | -1.82 | 0.0077 | 2.43 | 0.0023 | -- | -- | 3,418.31 | -53.07 | -51.47 | -59.00 | -57.56 | -846.22 | -- | -23,615.70 | -137,873.80 | 4.42 | -- | 0.0015 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
Neogen Corp | 929.24m | 1.57m | 2.88bn | 2.64k | 1,844.66 | 0.9157 | 24.44 | 3.10 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.40 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
Corcept Therapeutics Incorporated | 523.53m | 118.02m | 2.90bn | 352.00 | 26.04 | 5.29 | 24.35 | 5.54 | 1.07 | 1.07 | 4.74 | 5.27 | 0.822 | 1.12 | 11.13 | 1,487,298.00 | 18.53 | 21.17 | 21.50 | 23.85 | 98.54 | 98.52 | 22.54 | 27.23 | 5.10 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
Xenon Pharmaceuticals Inc | 0.00 | -188.60m | 2.90bn | 251.00 | -- | 3.27 | -- | -- | -2.71 | -2.71 | 0.00 | 11.76 | 0.00 | -- | -- | 0.00 | -23.02 | -20.71 | -23.66 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
Ideaya Biosciences Inc | 15.50m | -128.89m | 2.91bn | 124.00 | -- | 3.07 | -- | 187.70 | -2.00 | -2.00 | 0.2416 | 12.51 | 0.0234 | -- | 64.20 | 125,032.30 | -19.44 | -19.17 | -20.27 | -21.05 | -- | -- | -831.35 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
Holder | Shares | % Held |
---|---|---|
Glazer Capital LLCas of 31 Mar 2024 | 1.45m | 0.96% |
Balyasny Asset Management LPas of 31 Mar 2024 | 1.30m | 0.86% |
UBS Securities LLCas of 31 Mar 2024 | 1.17m | 0.77% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 962.22k | 0.64% |
Carlson Capital LPas of 31 Mar 2024 | 950.46k | 0.63% |
Tang Capital Management LLCas of 31 Mar 2024 | 800.71k | 0.53% |
Slotnik Capital LLCas of 31 Mar 2024 | 655.52k | 0.44% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 636.02k | 0.42% |
Segantii Capital Management Ltd.as of 31 Mar 2024 | 463.47k | 0.31% |
Tudor Investment Corp.as of 31 Mar 2024 | 343.31k | 0.23% |